

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Jacobson Pharma Corporation Limited**

**雅各臣科研製藥有限公司**

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

### **VOLUNTARY ANNOUNCEMENT**

#### **BUSINESS UPDATE**

This announcement is made by Jacobson Pharma Corporation Limited (“**Company**”) on a voluntary basis.

Reference is made to the announcement of the Company dated 14 August 2018 in relation to subscription of new shares under the general mandate and letter of intent in relation to the feasibility studies on possible business co-operations (the “**Announcement**”) and the announcement of the Company dated 3 September 2018 in relation to completion of the issues of new shares under general mandate. Unless otherwise specified, terms used herein shall have the same meanings as those defined in the Announcement.

The Company was informed by Yunnan Baiyao Holdings Company Limited\* (雲南白藥控股有限公司) (“**Baiyao Holdings**”) and Yunnan Baiyao Group Co.,Ltd.\* (雲南白藥集團股份有限公司) (“**Yunnan Baiyao Group**”) that Baiyao Holdings will be merged into and absorbed by Yunnan Baiyao Group (“**Merger**”) in accordance with the applicable laws of the PRC and all assets and liabilities of Baiyao Holdings will be assumed by Yunnan Baiyao Group. Upon completion of the Merger, Yunnan Baiyao Group will be the sole remaining entity and Baiyao Holdings will cease to exist as a separate legal entity.

As at the date of this announcement, Baiyao Holdings held 200,000,000 shares of the Company (“**Shares**”), representing approximately 9.92% of the total number of issued Shares. Upon completion of the updating of the register of members of the Company, such 200,000,000 Shares will be held by Yunnan Baiyao Group.

The Company was further informed that Yunnan Baiyao Group will continue the exploration of feasibilities on business and other aspects of co-operations with the Company as referred in the LOI upon the updating of Yunnan Baiyao Group in the register of members of the Company. Further announcement will be made by the Company in accordance with the Listing Rules as and when required.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Jacobson Pharma Corporation Limited**  
**YIM Chun Leung**  
*Executive Director*

Hong Kong, 8 May 2019

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Wong Chi Kei, Ian as independent non-executive Directors.*

\* *English name for identification purpose only*